Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice

被引:1
|
作者
Nishimura, Koichi [1 ,2 ]
Kusunose, Masaaki [3 ]
Shibayama, Ayumi [4 ]
Nakayasu, Kazuhito [5 ]
机构
[1] Natl Ctr Geriatr & Gerontol, 7-430 Morioka Cho, Obu 4748511, Japan
[2] Clin Nishimura, 4-3 Kohigashi, Kuri Cho, Ayabe 6230222, Japan
[3] Natl Ctr Geriatr & Gerontol, Dept Resp Med, 7-430 Morioka Cho, Obu 4748511, Japan
[4] Natl Ctr Geriatr & Gerontol, Dept Nursing, 7-430 Morioka Cho, Obu 4748511, Japan
[5] Kondo PP Inc, Data Res Sect, 17-25 Shimizudani Cho, Tennoujiku, Osaka 5430011, Japan
关键词
chronic obstructive pulmonary disease (COPD); disease severity; Global Initiative for Chronic Obstructive Lung Disease (GOLD); STaging of Airflow obstruction by Ratio (STAR); St. George's Respiratory Questionnaire (SGRQ); COPD Assessment Test (CAT); AIR-FLOW LIMITATION; COPD; MORTALITY; EXACERBATIONS; PREDICTORS; DYSPNEA; INDEX; RATIO; FEV1; FVC;
D O I
10.3390/diagnostics14060646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV1/FVC ratio <0.70: STAR 1 >= 0.60 to <0.70, STAR 2 >= 0.50 to <0.60, STAR 3 >= 0.40 to <0.50, and STAR 4 <0.40. Purpose: The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. Methods: We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. Results: By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298-13.733), p = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George's Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. Conclusion: From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Markers of exacerbation severity in chronic obstructive pulmonary disease
    Luigi G Franciosi
    Clive P Page
    Bartolome R Celli
    Mario Cazzola
    Michael J Walker
    Meindert Danhof
    Klaus F Rabe
    E Della Oscar Pasqua
    Respiratory Research, 7
  • [42] Chronic obstructive pulmonary disease - diagnosis and classification of severity
    Viviers, P. J.
    van Zyl-Smit, R. N.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2015, 105 (09): : 786 - 788
  • [43] Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011
    Marcoa, Raquel
    Rodrigues, Daniela Marta
    Dias, Margarida
    Ladeira, Ines
    Vaz, Ana Paula
    Lima, Ricardo
    Guimaraes, Miguel
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 15 (01) : 21 - 26
  • [44] Chronic obstructive pulmonary disease severity and cardiovascular outcomes
    Curkendall, Suellen M.
    Lanes, Stephan
    de Luise, Cynthia
    Stang, Mary Rose
    Jones, Judith K.
    She, Dewei
    Goehring, Earl, Jr.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2006, 21 (11) : 803 - 813
  • [45] Chronic obstructive pulmonary disease exacerbation frequency and severity
    Stafyla, Eirini
    Kerenidi, Theodora
    Gourgoulianis, Konstantinos I.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2013, 8 : 533 - 534
  • [46] Prediction of Clinical Outcomes in Chinese Patients with Chronic Obstructive Pulmonary Disease Comparing the Global Initiative for Chronic Obstructive Lung Disease 2017 and 2013 Classifications
    Cui, Y.
    Chen, P.
    Dai, Z.
    Ma, Y.
    Chen, Y.
    Cai, S.
    Zeng, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [47] Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge
    Leong, Paul
    Macdonald, Martin I.
    Ko, Brian S.
    Bardin, Phil G.
    MEDICAL JOURNAL OF AUSTRALIA, 2019, 210 (09) : 417 - 423
  • [48] DOES DISEASE OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE SEVERITY AFFECT OUTCOME OF PULMONARY REHABILITATION?
    Cornish, L.
    Dyer, F.
    Bott, J.
    THORAX, 2008, 63 : A94 - A94
  • [49] Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice
    Boschetto, Piera
    Beghe, Bianca
    Fabbri, Leonardo M.
    Ceconi, Claudio
    RESPIROLOGY, 2012, 17 (03) : 422 - 431
  • [50] Chronic Obstructive Pulmonary Disease Diagnosis and GOLD Classification
    Virani, Ahmed
    Baltaji, Stephanie
    Young, Meilin
    Dumont, Tiffany
    Cheema, Tariq
    CRITICAL CARE NURSING QUARTERLY, 2021, 44 (01) : 9 - 18